Action CVR Medical - CVM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,015

Prix Achat

0,015

Prix Vente

0,02

Volume échangé

0,00 Fourchette du Jour 0,00

0,015 Plage de 52 semaines 0,015

Clôture Veille

0,015

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis

Statistically Significant Findings Published in Prestigious Journal of International Immunopharmacology VIENNA, Va., Feb. 22...

CEL-SCI Corporation Reports First Quarter 2010 Financial Results

Company Ends Quarter in Strongest Financial Condition Ever VIENNA, Va., Feb. 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM...

CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference

VIENNA, Va., Feb. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced that Geert Kersten, Chief Executive Officer, will...

CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations

VIENNA, Va., Jan. 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a late-stage oncology company and a developer of vaccines...

CEL-SCI Corporation Announces 2009 Financial Results

Company Ends Fiscal Year in Strongest Financial Condition Ever; Receives Clean and Unqualified Audit Opinion VIENNA, Va., Jan. 13...

CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine

Facility Is Also Expected to Generate Revenue Through Contract Manufacturing VIENNA, Va., Jan. 11 /PRNewswire-FirstCall/ -- CEL-SCI Corporation...

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

VIENNA, Va., Dec. 1 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and a developer of vaccines...

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients

VIENNA, Va., Nov. 18 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention...

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

STUDIES SUPPORTIVE OF ROLE THAT TECHNOLOGY CAN PLAY IN TREATMENT OF H1N1 HOSPITALIZED PATIENTS VIENNA, Va., Nov. 9 /PRNewswire-FirstCall/...

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns

VIENNA, Va., Nov. 6 /PRNewswire/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0.015	0.015	0.015	0	0	CS
4	0	0	0.015	0.015	0.015	0	0	CS
12	0	0	0.015	0.015	0.015	0	0	CS
26	0	0	0.015	0.015	0.015	0	0	CS
52	0	0	0.015	0.015	0.015	0	0	CS
156	-0.01	-40	0.025	0.025	0.015	954	0.02141617	CS
260	-0.185	-92.5	0.2	0.2	0.015	54488	0.04319827	CS

CVM - Frequently Asked Questions (FAQ)

What is the current CVR Medical share price?

The current share price of CVR Medical is $ 0,015

What is the 1 year trading range for CVR Medical share price?

CVR Medical has traded in the range of $ 0,015 to $ 0,015 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MOONBlue Moon Metals Inc	$ 3,00 (745,07%)	8,11k
TVITVI Pacific Inc	$ 0,015 (200,00%)	3,83M
KUR.HKure Technologies Inc	$ 0,10 (100,00%)	3k
FRAS.PFraser Big Sky Capital Corp	$ 0,20 (100,00%)	7,02k
ZENI.PZenith Captal Corporation	$ 0,10 (100,00%)	1 000
HCM.HHighcliff Metals Inc	$ 0,02 (-60,00%)	3k
OVL.HOlivier Ventures Inc	$ 0,01 (-60,00%)	58k
MPTH.HMapath Capital Corp	$ 0,015 (-50,00%)	1 000
ALMAlliance Mining Corp	$ 0,10 (-50,00%)	500
PTEPioneering Technology Corp	$ 0,01 (-50,00%)	9k
AFMAlphamin Resources Corp	$ 0,57 (23,91%)	5,31M
QNCQuantum Emotion Corp	$ 0,71 (26,79%)	4,66M
TRBETribe Property Technolgies Inc	$ 0,50 (4,17%)	3,97M
TVITVI Pacific Inc	$ 0,015 (200,00%)	3,83M
FMNFidelity Minerals Corporation	$ 0,025 (-28,57%)	3,05M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

CVR Medical Corporation (CVM)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

CVM Dernières nouvelles

CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis

CEL-SCI Corporation Reports First Quarter 2010 Financial Results

CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference

CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations

CEL-SCI Corporation Announces 2009 Financial Results

CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns

CVM - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

CVR Medical Corporation (CVM) Cours

CVR Medical Corporation (CVM)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

CVM Dernières nouvelles

CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis

CEL-SCI Corporation Reports First Quarter 2010 Financial Results

CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference

CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations

CEL-SCI Corporation Announces 2009 Financial Results

CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns

CVM - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités